Table 3 |
|||
|
Summary of Adverse Events |
|||
|
Adverse event |
AL tablets n = 133* (%) |
AL suspension n = 134* (%) |
p |
|
|
|||
|
Diarrhoea |
11 (8.3) |
10 (7.4) |
0.81 |
|
|
|||
|
Vomiting during treatment** |
21 (2.6) |
12 (3.0) |
0.72 |
|
|
|||
|
Rhinitis |
17(12.8) |
22 (16.4) |
0.40 |
|
|
|||
|
Otitis Media |
1 (0.8) |
5 (3.7) |
0.21 |
|
|
|||
|
Pneumonia |
3 (2.3) |
6 (4.5) |
0.50 |
|
|
|||
|
Bacterial skin infections |
5 (3.8) |
5 (3.7) |
1.00 |
|
|
|||
|
Fungal skin infections |
6 (4.5) |
5 (3.7) |
0.98 |
|
|
|||
|
Eczematous rash |
1(0.8) |
5 (3.7) |
0.21 |
|
|
|||
|
Contact dermatitis |
1 (0.8) |
1 (0.7) |
1.00 |
|
|
|||
|
Conjunctivitis |
6 (4.5) |
7 (5.2) |
0.98 |
|
|
|||
|
* n = total number of children randomized to the treatments ** Vomiting episodes as a proportion of number of treatment doses administered |
|||
|
Juma et al. Malaria Journal 2008 7:262 doi:10.1186/1475-2875-7-262 |
|||
